Cochlear Ltd - Company Profile
Powered by 
All the data and insights you need on Cochlear Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Cochlear Ltd Strategy Report
- Understand Cochlear Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Cochlear Ltd (Cochlear) is a medical device company that offers implantable hearing solutions to the customers. It develops, manufactures, and markets electronic implantable hearing devices. The company’s products are suited for people with hearing loss caused by ear nerve damage. Its major products include cochlear implant systems, bone conduction systems, acoustic implants, bone anchored prosthetics and wireless accessories including wireless mini microphone, wireless phone clip and wireless television streamer. It has manufacturing facilities and regional distribution centers in North America and Europe. The company conducts its operations in the Asia-Pacific, Americas, the Middle East and Europe. The company markets its products through subsidiaries, local offices, distributors and agents. Cochlear is headquartered in Sydney, New South Wales, Australia.
Headquarters
Australia
Address
1 University Avenue, Macquarie University, Sydney, New South Wales, 2109
Website
www.cochlear.com/sg/en/home
Telephone
61 2 94286555
No of Employees
4,800
Industry
Medical Equipment
Ticker Symbol & Exchange
COH (ASX)
Revenue (2022)
$1.3B
17.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
4%
(2022 vs 2021)
Market Cap*
$13.4B
Net Profit Margin (2022)
XYZ
-11.5%
(2022 vs 2021)
* As of and is in US$
Cochlear Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Bone Anchored Implants: | Nucleus |
| Baha System and Accessories: | ESPrit |
| Titanium Implant and Osseointegration | Softip |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In August, the company launched its next-generation active bone conduction system, the Cochlear Osia System. |
| 2022 | Regulatory Approval | In November, the company received the US Food and Drug Administration approval for the Cochlear Nucleus 8 Sound Processor. |
| 2022 | Contracts/Agreements | In April, the company entered into an agreement to acquire Oticon Medical for US$170 million. |
Competitor Comparison
| Key Parameters | Cochlear Ltd | Sonova Holding AG | Demant A/S | Rion Co Ltd | GN ReSound Pty. Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Switzerland | Denmark | Japan | Australia |
| City | Sydney | Staefa | Smoerum | Kokubunji-Shi | - |
| State/Province | New South Wales | - | - | Tokyo | - |
| No. of Employees | 4,800 | 17,608 | 21,623 | 998 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alison Deans | Chairman | Executive Board | 2021 | - |
| Dig Howitt | Managing Director; Director; Chief Executive Officer; President | Executive Board | 2018 | - |
| Stuart Sayers | Chief Financial Officer | Senior Management | 2021 | - |
| Karen O’Driscoll | Chief Information Officer | Senior Management | 2023 | - |
| Jan Janssen | Chief Technology Officer | Senior Management | 2017 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward